Evidence map›Paper›PMID 42514140›Full record

ArticleLife (Basel, Switzerland)2026

Social Network Clustering Analysis for Detection of Associated Genetic Co-Mutations in Patients with Actionable Driver Mutations in NSCLC.

Abed Agbarya, Haitham Nasrallah, Kamel Mhameed, Edmond Sabo, Walid Shalata, Esti Liani, Salam Mazareb, Mohammad Sheikh-Ahmad, Leonard Saiegh, Dejan Radonjic and 2 more

Abstract read
In one paragraph

Article in Life (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Abed AgbaryaThe Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa 3109601, Israel.ORCID 0000-0002-3330-2959
Haitham NasrallahThe Joseph Fishman Oncology Center, Rambam Medical Center, Haifa 3525409, Israel.
Kamel MhameedThe Joseph Fishman Oncology Center, Rambam Medical Center, Haifa 3525409, Israel.
Edmond SaboPathology Institute, Lady Davis Carmel Medical Center, Haifa 3436212, Israel.
Walid ShalataThe Legacy Heritage Cancer Center, Dr. Larry Norton Institute, Soroka Medical Center, Beer Sheva 8457108, Israel.ORCID 0000-0002-7570-4550
Esti LianiPathology Institute, Lady Davis Carmel Medical Center, Haifa 3436212, Israel.
Salam MazarebPathology Institute, Lady Davis Carmel Medical Center, Haifa 3436212, Israel.
Mohammad Sheikh-AhmadInstitute of Endocrinology, Bnai-Zion Medical Center, Haifa 3339419, Israel.
Leonard SaieghInstitute of Endocrinology, Bnai-Zion Medical Center, Haifa 3339419, Israel.ORCID 0000-0001-5771-6569
Dejan RadonjicFaculty of Medicine and Dentistry, Palacky University, Hnevotinska Street 3, 77515 Olomouc, Czech Republic.
Viktor SebekDepartment of Pharmacology, Faculty of Medicine and Dentistry, Palacky University, Hnevotinska Street 3, 77515 Olomouc, Czech Republic.
Dan Levy-FaberThe Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa 3109601, Israel.ORCID 0000-0003-4558-4858

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-small cell lung cancer (NSCLC) exhibits genomic heterogeneity that affects tumor immunogenicity and PD-L1 expression. Patient clustering based on shared mutational profiles using social network analysis (SNA) has been narrowly explored. The study aimed to identify subgroups of NSCLC patients with similar somatic mutation profiles using network-based modularity clustering, and to compare these groups with respect to PD-L1 expression, Tumor mutation burden (TMB), and clinical variables. Data of patients with stage 4 (metastatic) NSCLC, whose tumor tissue samples were collected between 2022 and 2024, were analyzed. This retrospective study included NSCLC patients harboring actionable driver mutations in genes such as

Indexed as

actionable driver mutationsco-mutationsnon-small cell lung cancer (NSCLC)programmed death-ligand (PD-L1)social network analysis (SNA)tumor mutation burden (TMB)

Identifiers

PMID42514140
PMCPMC13412184

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.